REMARKS

Claims 22-51 presently appear in this case. The present amendment is being made to correct a clerical error made at the time of presentation of applicant's amendment of Janaury 25, 2002. All of new clams 38-51 were meant to depend ultimately from claim 36, not claim 37. As presently appearing, many of the claims are duplicative.

Accordingly, consideration of the present Supplemental Amendment in conjunction with applicant's Amendment of January 25, 2002, is earnestly solicited.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made".

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C. Attorneys for Applicant(s)

Ву

Roger L. Browdy

Registration No. 25,618

RLB:rd

Telephone No.: (202) 628-5197 Facsimile No.: (202) 737-3528

f:\,P\phaq\ToveylA\Pto\Amendmentf.doc

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Rae Dethlefsen	
Name	
Signature	
Didiracare	
- 1 26 2002	
February 26, 2002	
Date	

Version with Markings to Show Changes Made

Claims 38-41, 44 and 46-49 have been amended as follows:

- 38 (NewAmended). The method of claim 3736 in which the effective dose of interferon is administered in a single dose which is not a multiple or continuous dose.
- 39 (NewAmended). The method of claim 3736, in which the effective dose of interferon is administered intranasally, in a plurality of smaller doses over a period of time sufficient to elicit a response equivalent to that of a single dose.
- 40 (NewAmended). The method of claim 3736, in which an effective dose of interferon is administered intranasally continuously over a period of time sufficient to elicit a response equivalent to that of a single dose.
- 41 (NewAmended). The method of claim $\frac{3736}{}$, wherein the interferon comprises a Type I interferon.
- 44 (New Amended). The method of claim 3736, wherein the interferon comprises a Type II interferon.
- 46 (New Amended). The method of claim $\frac{3736}{10}$, wherein the dose of interferon is up to about 1000×10^6 IU of interferon.

- 47 (NewAmended). The method of claim $\frac{3736}{10}$, wherein the dose of interferon is from up to about 500 \times 10⁶ IU of interferon.
- 48 (New<u>Amended</u>). The method of claim 3736, wherein the dose of interferon is from about 50 \times 10⁶ IU to about 500 \times 10⁶ IU of interferon.
- 49 (New<u>Amended</u>). The method of claim 3736, wherein the viral infection is selected from the group consisting of rhinovirus, influenza, herpes varicella, herpes zoster, dengue fever, viral encephalitis, haemorrhagic fever, genital herpes, equine morbillivirus, hepatitis B, hepatitis C, hepatitis D, CMV, HIV, HPV, HSV- I and HSV-2.